lutetium has been researched along with n,n'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine n,n'-diacetic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Seth, A; Tripathi, M; Yadav, MP | 1 |
| Alexoff, D; Choi, SR; Kung, HF; Li, L; Ploessl, K; Yao, X; Zha, Z; Zhao, R; Zhu, L | 1 |
2 other study(ies) available for lutetium and n,n'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine n,n'-diacetic acid
| Article | Year |
|---|---|
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Edetic Acid; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
Topics: Albumins; Animals; Antigens, Surface; Cell Line, Tumor; Chelating Agents; Edetic Acid; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Mice; Prostatic Neoplasms; Radioisotopes; Tissue Distribution | 2022 |